Microsoft Corporation (NASDAQ:MSFT) has 3.00% insider ownership while its institutional ownership stands at 73.90%. In last trading activity company’s stock closed at $46.70. Microsoft Corp. (NASDAQ:MSFT) is evaluating a bid for Salesforce.com Inc., after the cloud software provider was approachedRead More

Regulus Therapeutics Inc. (NASDAQ:RGLS), announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis CRead More

On 30 January, Calithera Biosciences, Inc. (NASDAQ:CALA), announced the appointment of Dr. Keith Orford, M.D. Ph.D., as Vice President of Clinical Development. He joins the company following a distinguished career in oncology pharmaceuticals development, including senior clinical roles with GlaxoSmithKlineRead More

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymeraseRead More

On 3 February, Gilead Sciences, Inc. (NASDAQ:GILD) announced its results of operations for the fourth quarter and full year 2014. Total revenues for the fourth quarter of 2014 were $7.3 billion compared to $3.1 billion for the fourth quarter ofRead More

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced the pricing of an underwritten public offering of an aggregate 4,444,444 shares of its common stock and warrants to purchase an aggregate of 3,333,333 shares of the Company’s common stock at a combined priceRead More

Cambrex Corporation. (NYSE:CBM) reported Fourth quarter 2014 sales increased 25% to $128.8 million from $103.0 million in the same period last year. Full year 2014 sales increased 18%, and 19% excluding the impact of foreign currency. On Friday shares ofRead More

Trovagene, Inc. (NASDAQ: TROV), announced the pricing of an underwritten public offering of 4,444,444 shares of its common stock. The gross proceeds to Trovagene from this offering are expected to be approximately $20 million, before deducting underwriting discounts and commissionsRead More

On 29 January, Genetic Technologies Limited (NASDAQ: GENE) reported that up to 6 new breast diagnosis/treatment centres are expected to begin offering BREVAGenplus® to their at-risk patients in a systematic broad fashion in the January to March timeframe, with aRead More

Gilead Sciences Inc. (NASDAQ:GILD) reported Total revenues of $7.3 billion were no comparison to the year-ago figure of $3.1 billion. Quarterly revenues were above the Zacks Consensus Estimate of $6.7 billion. Full-year 2014 revenues increased 122.2% to $24.9 billion, toppingRead More